2016 sales: $619 million
Takeda won FDA approval for blood pressure compound azilsartan, known as Edarbi, back in 2011, thumping meds like Novartis' Diovan and Daiichi Sankyo's Benicar in trials on the way to its green light.
By September 2013, though, the Japanese drugmaker had sold U.S. rights off to Atlanta-based Arbor Pharmaceuticals for an undisclosed upfront payment and the potential for milestone and royalty payments down the line.
On the other side of the world, though, Takeda still counts the med as a key seller in Japan, where it won approval in January 2012 as Azilva. In the drugmaker’s 2016 annual report, it listed the Azilva product family as one of four that would help it lead the Japanese pharma industry between fiscal years 2016 and 2018.
And Evaluate Pharma, for one, predicts the med will keep growing into the future. It pegs the med’s 2022 sales at $749 million.